Novo Nordisk Raises 2022 Outlook for Third Time as Wegovy and Ozempic Demand Soars in U.S.

Novo Nordisk raised its full-year sales and profit outlook for the third time this year due to strong demand for Wegovy and Ozempic in the U.S.

The company now expects sales growth of 32-38% and profit growth of 40-46% for 2022.

Novo became Europe's most valuable company this year thanks to demand for Wegovy and Ozempic.

The upgraded guidance came despite supply constraints on Wegovy that are expected to last into 2024.

Novo initially forecast 13-19% sales and profit growth for 2022 but has raised outlook several times due to higher than expected demand.